ecancer

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA

13 Dec 2012

Uncovering new targets for treatment of chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA

13 Dec 2012

Targeting the proteasome mechanism

Dr Stig Linder – Karolinska Institute, Stockholm, Sweden

7 Dec 2012

Effect of hypoxia on cancer progression and adaptive response

Dr Greg Semenza – John Hopkins, Baltimore, USA

7 Dec 2012

New agents and mTOR inhibitors

Dr David Sabatini – Whitehead Institute, Boston, USA

7 Dec 2012

Transcriptional regulation of endothelial cell differentiation

Dr Elisabetta Dejana – IFOM – University of Milan, Italy

22 Nov 2012

Regulating the p53 pathway

Dr David Lane – Agency for Science, Technology and Research, Singapore

21 Nov 2012

Modified stem cells for therapeutics applications

Dr Luigi Naldini – San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Italy

20 Nov 2012

Rap G Protein Signaling in Haematologic Malignancy

Dr Nagahiro Minato – Kyoto University Graduate School of Medicine, Japan

20 Nov 2012

Advances in haemato-oncological treatment options

Prof Kenneth Anderson – Dana Farber Cancer Institute, Boston, UK

15 Nov 2012

Treatment of antiphospholipid syndrome with aspirin

Prof Graham Hughes – St Thomas Hospital, London, UK

1 Nov 2012

Effects of aspirin on the progression of cancer

Prof Peter Rothwell – Oxford University, UK

1 Nov 2012

More from ecancer